Business Context and Reporting Period
This Form 6-K filing by GlaxoSmithKline plc covers the period ending December 30, 2014. The report serves as a notification of transactions involving directors, persons discharging managerial responsibility, or connected persons, in accordance with DTR 3.1.4 R(1)(a) and (c).
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is strictly a disclosure of share transactions and does not contain financial performance data.
Material Changes
The filing details specific share movements for Sir Andrew Witty and his connected person on December 29 and 30, 2014:
- Transfer of 1,082 Ordinary Shares from a nominee holding to a Connected Person.
- Sale of 1,075 Ordinary Shares at 1397.77p per share.
- Repurchase of 1,066 Ordinary Shares at 1398.38p per share.
- Transfer of 7 Ordinary Shares to Sir Andrew Witty's nominee holding.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary, risks, contingencies, or unusual items. The document is limited to the notification of the aforementioned director transactions.
Investor Verification Points
- Verify the total net change in shareholding for Sir Andrew Witty and his connected person following the December 29 and 30 transactions.
- Confirm the pricing of the sale (1397.77p) and repurchase (1398.38p) against the market price on the transaction date.
- Review the full annual report (Form 20-F) for comprehensive financial metrics, as this 6-K filing contains none.